Holdings
VanEck Pharmaceutical ETF
As of Jun 30, 2026, VanEck Pharmaceutical ETF reported 25 positions worth US$875M. Largest: Eli Lilly And Company, Novartis Ag and Merck & Company, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly And Company | 148K | US$178M | −113K | Jun 30, 2026 |
| Novartis Ag | 598K | US$93.4M | −314K | Jun 30, 2026 |
| Merck & Company, Inc. | 674K | US$86.6M | −361K | Jun 30, 2026 |
| Novo Nordisk A/s Class B | 998K | US$47.2M | −648K | Jun 30, 2026 |
| Abbvie Inc. | 160K | US$40.2M | −83,678 | Jun 30, 2026 |
| Pfizer, Inc. | 1.65M | US$39.6M | −748K | Jun 30, 2026 |
| Bristol-myers Squibb Company | 682K | US$39.3M | −299K | Jun 30, 2026 |
| Gsk Plc | 1.47M | US$38.9M | −673K | Jun 30, 2026 |
| Johnson & Johnson | 151K | US$38.3M | −77,416 | Jun 30, 2026 |
| Astrazeneca Plc | 201K | US$38.1M | −85,893 | Jun 30, 2026 |